Effects of LP28 on Immunity Enhancement in the Elderly
1 other identifier
interventional
100
1 country
2
Brief Summary
Due to the increasing attention on aging-related health issues, this study focuses on the elderly population as participants. The aim is to investigate whether supplementation with Lactobacillus plantarum LP28 can effectively enhance immunity, reduce the frequency and severity of common cold infections, and ultimately promote overall health in the elderly.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2024
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 9, 2024
CompletedFirst Submitted
Initial submission to the registry
December 4, 2024
CompletedFirst Posted
Study publicly available on registry
December 9, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedDecember 9, 2024
December 1, 2024
12 months
December 4, 2024
December 4, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
WURSS-24
The WURSS-24 (Wisconsin Upper Respiratory Symptom Survey-24) is a questionnaire designed to assess the impact of upper respiratory tract infections, such as the common cold, on daily life and health. It includes 24 questions covering symptoms (e.g., cough, runny nose, fatigue) and how they affect daily activities, work, and social interactions. Patients rate each item on a scale from 0 (no problem) to 7 (severe problem).
From enrollment to the end of treatment at 12 weeks (measure daily)
Secondary Outcomes (7)
Immune cell ratio
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
NK cell activity
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
Cytokines measurement
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
sIgA
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
α-amylase
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
- +2 more secondary outcomes
Study Arms (2)
LP28 capsule
EXPERIMENTALSubjects will take two capsule of the experimental group(LP28 capsule) within 30 minutes before breakfast and dinner each day.
Placebo capsule
PLACEBO COMPARATORSubjects will take two placebo capsule within 30 minutes before breakfast and dinner each day.
Interventions
Eligibility Criteria
You may qualify if:
- Those who had symptoms of common cold or tonsillitis at least twice in the past year.
You may not qualify if:
- People who have liver, kidney, immune, or neoplastic diseases diagnosed by doctor.
- People with mental illnesses such as schizophrenia or depression.
- People who have allergic rhinitis.
- People who have a current condition of drug or alcohol dependence.
- Any person is deemed inappropriate by the researcher for the clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Synbio Tech Inc.lead
Study Sites (2)
National Chung Hsing University
Taichung, 402202, Taiwan
Taichung Veterans General Hospital
Taichung, 407219, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 4, 2024
First Posted
December 9, 2024
Study Start
July 9, 2024
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
December 9, 2024
Record last verified: 2024-12